# Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

> **NCT06600022** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 441 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumours

## Interventions

- **DRUG:** SCTB41

## Key facts

- **NCT ID:** NCT06600022
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 441 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600022, "Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06600022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*